XML 80 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Assets and Liabilities Measured at Fair Value - Narrative (Details)
 3 Months Ended
Mar. 31, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Financial assets and liabilities subject to fair value measurements      
Contingent consideration payable   $ 20,339,000 $ 25,825,000
Milestone payment, stock issued as consideration $ 771,804    
Level 3      
Financial assets and liabilities subject to fair value measurements      
Contingent consideration payable   20,339,000 $ 25,825,000
Callidus | Clinical and Regulatory Approval Milestones | ATB-200 Pompe Program | Probability weighted discounted cash flow      
Financial assets and liabilities subject to fair value measurements      
Contingent consideration payable   $ 18,883,000  
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Minimum      
Financial assets and liabilities subject to fair value measurements      
Contingent consideration, measurement input   0.75  
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Maximum      
Financial assets and liabilities subject to fair value measurements      
Contingent consideration, measurement input   0.88  
Callidus | Clinical and Regulatory Approval Milestones | Level 3 | Discount rate | ATB-200 Pompe Program      
Financial assets and liabilities subject to fair value measurements      
Contingent consideration, measurement input   0.075